investor_presentation
Kaleyra
Loading viewer...
investor_presentation
Format: PDF investor_presentation
1 ©2021 KARYOPHARM THERAPEUTICS INC. Business Highlights & Third Quarter 2021 Financial Results November 3, 2021
1 ©2021 KARYOPHARM THERAPEUTICS INC.
& Third Quarter 2021
November 3, 2021 2 ©2021 KARYOPHARM THERAPEUTICS INC. Joining for Q&A:
•Stephen Mitchener, PharmD
Chief Business Officer
•Sharon Shacham, PhD
Chief Scientific OfficerOn Today’s Call
Jason Finkelstein, Investor Relations, Argot Partners
Richard Paulson, President and Chief Executive Officer
•Commercial Highlights
Sohanya Cheng, SVP, Sales and Commercial Operations
•Clinical Pipeline Updates
Jatin Shah, MD, Chief Medical Officer
•Financial Summary and Guidance
Michael Mason, Chief Financial Officer
Richard Paulson, President and Chief Executive Officer
•Q&A Session 3 ©2021 KARYOPHARM THERAPEUTICS INC. Forward -looking Statements and Other Important Information
This presentation contains forward -looking statements within themeaning ofThe Private Securities Litigation Reform Actof1995 .Such forward -looking statements include those regarding Karyopharm’s
guidance onKaryopharm’s 2021 non-GAAP research anddevelopment andselling, general andadministrative expenses ;Karyopharm’s expected cash runway ;expectations andplans relating toXPOVIO for
thetreatment ofadult patients with relapsed orrefractory multiple myeloma orrelapsed orrefractory diffuse large B-celllymphoma andother hematologic malignancies andsolid tumors ;commercialization of
XPOVIO oranyofKaryopharm’s drug candidates andthecommercial performance ofXPOVIO ;submissions to,andthereview andpotential approval ofselinexor oreltanexor by,regulatory authorities,
including theCompany’s regulatory strategy, theanticipated availability ofdata tosupport such submissions, timing ofsuch submissions andactions byregulatory authorities andthepotential availability of
accelerated approval pathways ;theexpected design oftheCompany’s clinical trials ;andthetherapeutic potential ofandpotential clinical development plans forKaryopharm's drug candidates, especially
selinexor oreltanexor .Such statements aresubject tonumerous important factors, risks anduncertainties, many ofwhich arebeyond Karyopharm's control, thatmay cause actual events orresults todiffer
materially from Karyopharm's current expectations .Forexample, there canbenoguarantee thatKaryopharm willsuccessfully commercialize XPOVIO ;thatregulators willgrant confirmatory approval inthe
European Union based ontheBOSTON study inadult patients with multiple myeloma ;orthatanyofKaryopharm’s drug candidates, including selinexor oreltanexor, willsuccessfully complete necessary
clinical development phases orthat development ofany ofKaryopharm’s drug candidates willcontinue .Further, there can benoguarantee that any positive developments inthedevelopment or
commercialization ofKaryopharm’s drug candidate portfolio willresult instock price appreciation .Management’s expectations and, therefore, anyforward -looking statements inthispress release could also be
Preview truncated — download the full document for the complete content.
conference
34 Pages
investor_presentation
19 Pages
Teck Resources Limited
investor_presentation
Kaleyra